Nvronrabi 20mg Tablet contains Rabeprazole, a proton pump inhibitor (PPI) indicated for the treatment of acid-related gastrointestinal conditions. Rabeprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This reduction in acid production provides symptomatic relief and promotes healing in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and peptic ulcer disease, including Helicobacter pylori-associated ulcers when used in combination therapy. Nvronrabi is also employed for the prevention of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). The 20mg dosage is typically administered once daily, preferably before meals, to optimize efficacy. Rabeprazole is generally well-tolerated; however, potential adverse effects may include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use should be monitored due to possible risks such as vitamin B12 deficiency, hypomagnesemia, and increased susceptibility to gastrointestinal infections. Caution is advised in patients with hepatic impairment, and drug interactions should be considered, particularly with medications dependent on gastric pH for absorption. Nvronrabi 20mg Tablet should be used under medical supervision to ensure appropriate indication and dosing.